Improving the ACS Triage-Using High Sensitivity TroponinI and Copeptin for Early 'Rule-Out' of AMI

Area of Science:

• Cardiology
• Emergency Medicine
• Biomarker Research

Background:

• Diagnosing acute myocardial infarction (AMI) in emergency departments (EDs) presents challenges, especially for patients with early symptom onset.
• Current methods using high-sensitivity troponin (hs-Tn) may not detect AMI within the first 3-6 hours.

Purpose of the Study:

• To evaluate a protocol combining copeptin and hs-TnI testing for earlier AMI diagnosis in chest pain patients.
• To determine if this dual-biomarker approach can prevent major adverse cardiac events compared to standard protocols.

Main Methods:

• A study involving 148 patients presenting with chest pain within 6 hours of symptom onset.
• Utilized a dual biomarker protocol including copeptin and hs-TnI at emergency department admission.

Main Results:

• The combined copeptin and hs-TnI testing achieved 100% sensitivity and 99.8% negative predictive value for ruling out AMI at presentation.
• This dual-biomarker strategy could potentially rule out AMI in over two-thirds of patients, avoiding prolonged ED stays and repeat testing.

Conclusions:

• Combined copeptin and hs-TnI testing offers a rapid and accurate method for ruling out AMI in the ED.
• This approach can significantly streamline patient management, reduce healthcare costs, and improve patient outcomes without compromising safety.